T3D-959

T3D Therapeutics, Inc. · Phase 2 active Small molecule

At a glance

Generic name	T3D-959
Sponsor	T3D Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects (PHASE2, PHASE3)
Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects (PHASE2)
Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

T3D-959 CI brief — competitive landscape report
T3D-959 updates RSS · CI watch RSS
T3D Therapeutics, Inc. portfolio CI